Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors
- Name
- Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors
- Accession Number
- DBCAT003788
- Description
Not Available
- Drugs
Drug Drug Description Alirocumab A PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C). Inclisiran A PCSK9-targeting short interfering RNA (siRNA) that lowers plasma LDL-cholesterol levels. - Drugs & Drug Targets
Drug Target Type Alirocumab Proprotein convertase subtilisin/kexin type 9 target Inclisiran Proprotein convertase subtilisin/kexin type 9 target